Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

Shots:

– The company has initiated a P-III ESLIM-01 trial to evaluate the efficacy and safety of HMPL-523 in 180 adult patients with ITP. The study is based on the results of the P-Ib study in patients with the same indication

– The 1EPs of the study is the DRR.…